• Mini-Lungs In A Dish, Airway Stem Cells, Evolution of Virus Mutations: COVID-19 Updates

    Bio-IT World I Neutrons chart atomic map of COVID-19’s viral replication, Organs-on-Chips technology, coronaviruses mimic proteins that control blood coagulation and inflammation, therapeutic effects of Chinese herbal medicine, crystal structure identified on SARS-CoV-2 papain-like protease, and potent antibody isolated. Plus: NIH researchers discover key pathway in lysosomes for coronaviruses exit, deep learning models to target SARS-CoV-2 main protease, RBD nanoparticles may be effective vaccine, predicting outbreaks, virus may ‘hide’ in asymptomatic people, and NYC outbreak linked to Europe.

    Oct 30, 2020

  • Follow the Money: Microbiome, ‘Omics, Vaccine Patches

    Bio-IT World | Money for oral microbiome drugs, ‘omics, a biology plus technology transistor, digital biomarker platform, a vaccine patch that doesn’t require refrigeration, and more.

    Oct 28, 2020

  • Illumina Launches DRAGEN V3.7, Talks ML, Truth Challenges, All Of Us

    Bio-IT World | Illumina is launching version 3.7 of its DRAGEN bio-IT platform this week, Rami Mehio, Vice President, Bioinformatics and Instrument Software at Illumina, told Bio-IT World last week. The newest release will include DRAGEN for Single Cell RNA, unique molecular identifier (UMI) support including UMI-aware small variant calling, CYP2D6 genotyping, and accuracy gains in both germline variant calling and tumor-only analysis.

    Oct 27, 2020

  • Clinical Data Visualizations at BMS Merge Trial and Real-World Data

    Bio-IT World | The probability of success is low in early drug discovery and gets progressively more expensive on the journey to marketing approval by the Food and Drug Administration (FDA). To “fail early and fail often” has thus become the mantra of medicine developers needing to direct resources to the candidates most likely to triumph, says Philip Ross, director of translational bioinformatics data science at Bristol-Myers Squibb (BMS). Only 9.6% of drugs that make it to phase I trials ever get FDA approved.

    Oct 26, 2020